Articles related to LUNG CANCER

In the CodeBreaK 100 study, a lower 240 mg dose of sotorasib demonstrated similar efficacy to the FDA-approved 960 mg dose in treating KRAS G12C–mutated NSCLC, with potentially fewer severe adverse events.

UT Southwestern’s pioneering use of SCINTIX biology-guided radiotherapy represents a major advancement in precision oncology, targeting bone and lung cancers with a novel approach that combines PET imaging and radiotherapy for more effective treatment.

This study highlights repotrectinib’s remarkable efficacy in ROS1 fusion–positive NSCLC, demonstrating a notable response even in patients with the challenging ROS1 G2032R mutation, and presents a new potential standard in targeted lung cancer therapy.

An in-depth look at the FDA’s clinical hold on Iovance’s lung cancer cell therapy trial reveals crucial insights into the safety and progression of innovative cancer treatments.

A look into the FDA’s rigorous 2023 drug approval process, including a record number of new medicines and notable rejections. Understanding these trends is essential for anticipating future treatment landscapes.

In the intricate realm of chest X-ray interpretation, AI shines in detecting diseases but falls short in discerning their absence, especially in complex cases. Lead author Dr. Louis Plesner cautions against relying solely on AI, emphasizing the indispensable role of human radiologists.